MEK Inhibitor News and Research

RSS
Combinatory therapy may be effective in suppressing drug resistance in treatment of melanoma

Combinatory therapy may be effective in suppressing drug resistance in treatment of melanoma

New hope for patients whose melanoma has metastasised to the brain

New hope for patients whose melanoma has metastasised to the brain

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

New MDx prototype platform can detect BRAF V600 mutations in 90 minutes

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

Study compares spectrum of cancer-related gene mutations in two common types of cervical cancer

Study compares spectrum of cancer-related gene mutations in two common types of cervical cancer

Secondary cancers in melanoma patients treated for BRAF gene mutation require new strategies

Secondary cancers in melanoma patients treated for BRAF gene mutation require new strategies

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Array BioPharma achieves milestone for initiation of MEK162 Phase 3 trial in patients with LGSOC

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

Selumetinib demonstrates clinical benefit for patients with metastatic uveal melanoma

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

MITF protein may help develop effective drug treatments for melanoma

MITF protein may help develop effective drug treatments for melanoma

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Paper illuminates importance of PKM2 in cancer development and progression

Paper illuminates importance of PKM2 in cancer development and progression

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Sorafenib does not improve overall survival among patients with NSCLC

Sorafenib does not improve overall survival among patients with NSCLC

Drug combinations show promise against metastatic melanoma

Drug combinations show promise against metastatic melanoma

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Novel drug combination for patients with NRAS-mutant melanoma

Novel drug combination for patients with NRAS-mutant melanoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.